CAR-T Therapy Clears Two Walls at Once: Solid Tumors and the Price Tag

CAR-T therapy spent most of the last decade proving it could work at all. Across 2025 and 2026, the more interesting question has become whether it can work for more people, in more places, against more types of cancer, without every gain coming at the cost of a six- or seven-figure price tag. This piece sets the market-sizing numbers in our companion report aside and focuses on what is actually moving in regulation, manufacturing, and patient access across the past two years.

A Regulatory Shortcut Just Got Shorter

Every CAR-T therapy approved in the US before 2024 carried a Risk Evaluation and Mitigation Strategy, a layer of mandatory hospital certification and patient monitoring built around the risk of cytokine release syndrome and neurological side effects. That started to change in November 2024, when the FDA approved Autolus' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia without a REMS requirement at all, the first CAR-T product to reach the US market on that basis. Company trial data showed a low rate of severe cytokine release syndrome, which the FDA appears to have weighed in the decision.

The bigger move came seven months later. On June 26, 2025, the FDA removed the REMS requirement entirely for six already-approved CD19 and BCMA-directed autologous CAR-T products: Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, and Yescarta. Boxed warnings, patient medication guides, and extended follow-up requirements all stay in place, so this is not a safety rollback. What it removes is the separate certification and monitoring process that made it harder for a new hospital to start offering these therapies, which should in theory let more treatment centers come online without changing who is medically eligible for CAR-T in the first place.

Source: GlobeNewswire, Autolus Therapeutics Announces FDA Approval of AUCATZYL (Nov 8, 2024); FDA Statement on Removal of REMS Requirements for Autologous CAR T Cell Products (Jun 26, 2025).

The Real Constraint Is Still the Tank, Not the Patient

Loosening the regulatory side does nothing for a patient if a manufacturer cannot turn a blood draw into an infused product fast enough. Legend Biotech and J&J used their March 2025 earnings call to lay out a plan to double Carvykti manufacturing supply over the course of the year, adding capacity at a new Raritan, New Jersey site and at their Ghent, Belgium campus, with a target of exiting 2025 with around ten thousand manufacturing slots. Analysts covering the stock have been blunt about why this matters: the number of available commercial manufacturing slots, not patient demand, is expected to be the main driver of Carvykti revenue over the following year.

Allogeneic, donor-derived CAR-T has long been pitched as the way around this bottleneck, since it removes the need to manufacture a separate batch for every single patient. Allogene Therapeutics opened 2026 by calling it a defining year for its platform, pointing to mid-stage data expected across several programs, including a kidney cancer candidate that had already shown a confirmed response rate above 30 percent in patients with high target expression. That is a real result, but it is also a reminder of where the technology still stands: more than a decade after the first autologous CAR-T approval, no allogeneic product has yet matched autologous therapy's durability in a pivotal trial, which is why autologous manufacturing capacity, not allogeneic promise, is still what determines how many patients can be treated this year.

Solid Tumors' First Real Win

CAR-T therapy has worked against blood cancers for years and has mostly failed against solid tumors, where dense tissue and an immune-suppressing environment around the tumor make it harder for engineered T-cells to reach and act on cancer cells. That changed in 2026, when China's NMPA approved CARsgen Therapeutics' satricabtagene autoleucel, the first CAR-T therapy cleared anywhere for a solid tumor, for patients with CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction cancer. Trial results behind the approval showed a meaningful reduction in the risk of disease progression and a tumor shrinkage rate in more than half of treated patients.

One approval in one country does not settle the solid tumor question. It does give every other developer working on a solid tumor antigen, whether CLDN18.2 in a different cancer type or an entirely different target such as mesothelin, a concrete regulatory precedent to point to in their own discussions with health authorities, which is the kind of thing that tends to move an entire subfield faster than any single company's own data can.

Two Countries Building Their Own Supply

Affordability, more than biology, is what keeps CAR-T out of reach for most patients outside the US and Western Europe. Two countries took a similar approach to that problem in the past year, each by building supply at home rather than waiting for imported therapy to get cheaper. South Korea's Ministry of Food and Drug Safety approved Curocell's Limkato in April 2026, the country's first domestically developed CAR-T therapy, under a fast-track review the ministry has used to pilot parallel drug approval, reimbursement assessment, and price negotiation, specifically to shorten the time between approval and patient access.

India took a different route to roughly the same goal. ImmunoACT's NexCAR19, the country's first commercial CAR-T therapy, was already priced below comparable imported products when it launched, and in December 2025 ImmunoACT partnered with Mango Sciences to layer on zero-interest financing and a separate outcomes-linked payment option, each covering a meaningful share of treatment cost for eligible patients. The companies describe it as one of the first attempts anywhere to attach a value-based payment model to CAR-T therapy. Whether or not that claim holds up as a global first, the direction is clear: markets that cannot simply wait for list prices to fall elsewhere are building their own paths to access, through domestic manufacturing in Korea and through financing innovation in India.

Related Vectomat Insights Coverage

This article provides editorial and R&D context only. For full market sizing, segmentation, regional share, competitive benchmarking and forecasts through 2035, see the companion CAR-T Cell Therapy Market Report.